Related Experiment Videos
Risk of adverse events with fibrates
Alawi A Alsheikh-Ali1, Jeffrey T Kuvin, Richard H Karas
1Molecular Cardiology Research Institute, Department of Medicine, Division of Cardiology, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Abstract:
An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis. This difference was especially noticeable in patients taking the combination of gemfibrozil and a statin, particularly cerivastatin.
Related Concept Videos
Drug toxicity: Drug–Drug Interaction
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drug Toxicity: Risk factors
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics: Drug–Drug Interactions
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow